Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941834 · ClinicalTrials.gov registry record · Phase 2
Trial for Treatment Refractory Trigeminal Neuralgia
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT03941834 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 65 participants.
The verdict
NCT03941834, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
Interventions
- DRUG Placebo
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941834
The ClinicalTrials.gov registry entry for NCT03941834 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03941834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03941834 about?
NCT03941834 is a clinical study titled "Trial for Treatment Refractory Trigeminal Neuralgia". The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
What is the current status of trial NCT03941834?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2019-06-25. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT03941834?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03941834?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.